Liver International最新文献

{"title":"Reactive Oxygen Species-Mediated TRPM2 Activation Facilitates Phagocytosis of Macrophages to Reverse Profibrotic Phenotype","authors":"Shaoying Zhang,&nbsp;Fanfan Liang,&nbsp;Dan Wan,&nbsp;Chongyu Zhang,&nbsp;Yinggang Zhang,&nbsp;Xurui Zhang,&nbsp;Na Huang,&nbsp;Keping Feng,&nbsp;Xiao Liang,&nbsp;Ni Guo,&nbsp;Chen Zhang,&nbsp;Zhe Zhou,&nbsp;Yuehua Li,&nbsp;Jing Geng,&nbsp;Pengfei Liu,&nbsp;Guangyao Kong,&nbsp;Shemin Lu,&nbsp;Zongfang Li","doi":"10.1111/liv.70341","DOIUrl":"https://doi.org/10.1111/liv.70341","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Macrophages play plastic roles during fibrogenesis and fibrosis regression. Phagocytosis is considered a trigger for shifting macrophages from a profibrotic phenotype to a restorative phenotype. However, the underlying mechanism by which macrophages enhance phagocytosis remains unclear. Our present study investigated the role of reactive oxygen species (ROS)-modulated TRPM2 activation in this process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The changes of TRPM2 expression, ROS intensity, and macrophage phagocytosis were assessed in fibrogenesis and fibrosis regression models. RNA sequencing was utilised to reveal pathway enrichment caused by TRPM2, and the role of TRPM2 in enhancing phagocytosis was verified. The coordinate regulation of ROS-TRPM2 in different functions of macrophages was demonstrated by modulating ROS intensity and TRPM2 expression. Mitochondrial dynamics changes induced by ROS-stimulated TRPM2 activation were evaluated by analysing the expression of dynamics-related molecules and mitochondrial imaging, and intervention in mitochondrial dynamics confirmed their impact on macrophage phagocytosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Low-intensity ROS stimulation up-regulated the expression of TRPM2 and coordinately enhanced macrophage phagocytosis and the expression of matrix degradation-related proteins (MMPs), a process akin to fibrosis regression. However, high-intensity ROS inclined macrophages to produce more profibrotic cytokines, associating with oxidative stress caused by liver injury. ROS-mediated TRPM2 activation mobilised Ca²⁺ and promoted mitochondrial fission; either inhibiting mitochondrial fission or chelating Ca²⁺ counteracted phagocytosis, as well as decreasing MMPs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>ROS-TRPM2 coordinately regulate macrophage functions. During the liver fibrosis regression period, ROS-induced activation of TRPM2 helps enhance macrophage phagocytosis and switches them to a restorative phenotype. Modulating this process may provide means for developing effective therapeutic strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70341","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to Editor—Expanding the Horizons of TIPS and SEMS Research in Refractory Variceal Bleeding Management","authors":"Sushrut Singh,&nbsp;Vinod Arora,&nbsp;Shiv Kumar Sarin","doi":"10.1111/liv.70344","DOIUrl":"https://doi.org/10.1111/liv.70344","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction-Related Immunoglobulins Predicting Outcomes in ACLF","authors":"Boglarka Balogh,&nbsp;David Tornai,&nbsp;Aniko Csillag,&nbsp;Istvan Tornai,&nbsp;Zsuzsana Vitalis,&nbsp;Patricia Kovats,&nbsp;Peter Antal-Szalmas,&nbsp;Tamas Dinya,&nbsp;Wim Laleman,&nbsp;Minneke J. Coenraad,&nbsp;Jonel Trebicka,&nbsp;Maria Papp,&nbsp;MICROB-PREDICT and PREDICT study group of the EASL-CLIF consortium","doi":"10.1111/liv.70350","DOIUrl":"https://doi.org/10.1111/liv.70350","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>In cirrhosis, impaired gut mucosal immunity facilitates bacterial translocation (BT) instigating the proinflammatory cascade that exacerbates hepatic damage. The role of antibody-mediated immunity in this process remains unclear. We assessed serum immunoglobulins (Ig) linked to gut barrier function as prognostic markers in a prospective MICROB-PREDICT cohort of patients with acutely decompensated (AD) cirrhosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Serum samples of 128 patients were assayed for IgA and IgG antibodies against various targets (filamentous-actin; <i>Saccharomyces cerevisiae</i> [ASCA]; glycoprotein-2 [GP2]; gliadin; endotoxin-core [EndoCab]), secretory (s)IgA, total-IgA, IgG, IgM and free Ig kappa/lambda light chains. Mortality was assessed during a 3-month follow-up period. An independent ACLF patient cohort (<i>n</i> = 50) was used to validate sIgA-related findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>IgA-type target-specific antibodies were more prevalent than IgG types. Target-specific antibody diversity and concentrations, total-IgA levels and Child–Pugh severity exhibited concordant elevations. Total-IgG levels were inversely associated with CLIF-C AD score and presence of ACLF. sIgA levels increased in parallel with ACLF grades. Elevated sIgA levels were associated with 90-day mortality in ACLF patients (<i>n</i> = 37; AUROC: 0.859; at the cut-off of &gt; 20.9 μg/mL: 11.1% vs. 78.9% Mortality <i>p</i> &lt; 0.001). These findings were confirmed in the validation cohort. In the merged ACLF cohort (<i>n</i> = 87), high sIgA levels predicted 90-day mortality independent of CLIF-C ACLF score (HR: 3.367; CI: 1.563–7.225; <i>p</i> = 0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Enhanced BT-triggered immune activation is indicated by increased total-IgA levels in association with the occurrence of target-specific IgA antibodies. Serum sIgA is a promising marker of gut barrier failure and 90-day mortality in ACLF.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70350","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Genetic Predictors of Non-Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals","authors":"Karina Sato-Espinoza,&nbsp;Robert A. Vierkant,&nbsp;Perapa Chotiprasidhi,&nbsp;Filippo Pinto e Vairo,&nbsp;Shulan Tian,&nbsp;Jun Ma,&nbsp;Daniel O'Brien,&nbsp;Konstantinos N. Lazaridis,&nbsp;Carola Dlugosch,&nbsp;Carolin Scheider,&nbsp;Alina M. Allen,&nbsp;Kirk J. Wangensteen","doi":"10.1111/liv.70300","DOIUrl":"https://doi.org/10.1111/liv.70300","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Steatotic liver disease (SLD) is characterised by liver fat accumulation exceeding 5%. Lean body weight (BMI ≤ 25 kg/m²) with non-alcoholic SLD is a rare phenotype, and the balance of risks related to metabolic conditions or genetic predisposition, or the risk of progressive liver disease, is not known. This study evaluates clinical and genetic predictors of non-alcoholic SLD and advanced liver disease in lean individuals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used International Classification of Disease codes, radiology and pathology review to identify 177 lean non-alcoholic SLD cases (47 cryptogenic, 130 MASLD), 677 matched lean controls, and 3090 overweight/obese SLD cases in the Mayo Clinic Biobank and Tapestry databases. We performed case–control and cross-sectional comparisons of clinical and genetic factors between these groups, using univariable and multivariable analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Lean individuals with non-alcoholic SLD exhibited metabolic and genetic profiles that were intermediate between those of lean controls without SLD and overweight/obese SLD individuals, including intermediate rates of diabetes, hypertension, hyperlipidaemia and of homozygosity for the risk allele of <i>PNPLA3</i>. Multivariable analysis indicated that diabetes was an independent predictor of SLD among lean individuals. Among lean individuals with non-alcoholic SLD, those with metabolic-associated SLD (MASLD), as compared to those with cryptogenic SLD (without metabolic risk factor), were more likely to be homozygous for risk alleles in <i>GCKR</i>. The Fib-4 score, a tool for screening advanced liver disease in SLD, accurately predicted advanced fibrosis among lean individuals with non-alcoholic SLD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Diabetes serves as a primary predictor of non-alcoholic SLD in lean individuals. These results support the recommendation to screen for SLD in patients with diabetes, regardless of BMI. The <i>GCKR</i> risk allele is associated with MASLD in lean individuals, and the risk factors for cryptogenic SLD remain unclear.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing ICI Liver Injury in HCC: Key Limitations","authors":"Yihui Shi,&nbsp;Tingting Li,&nbsp;Xinli Chen","doi":"10.1111/liv.70353","DOIUrl":"https://doi.org/10.1111/liv.70353","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor-Beta in Liver Tumorigenesis","authors":"Ana Cantos-Cortes,&nbsp;Josep Amengual,&nbsp;Rut Espinosa-Sotelo,&nbsp;Esther Bertran,&nbsp;Javier Vaquero,&nbsp;Marina Ruiz de Galarreta,&nbsp;Pedro Molina-Sanchez,&nbsp;Teresa Serrano,&nbsp;Emilio Ramos,&nbsp;Mariona Calvo,&nbsp;Rosanna Scialpi,&nbsp;Francesco Dituri,&nbsp;Gianluigi Giannelli,&nbsp;Amaia Lujambio,&nbsp;Ester Gonzalez-Sanchez,&nbsp;Isabel Fabregat","doi":"10.1111/liv.70351","DOIUrl":"https://doi.org/10.1111/liv.70351","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. TGF-β is a promising therapeutic target, but its dual role, as both a tumour suppressor and promoter, complicates its clinical application. While its effects on tumour cells are increasingly understood, its impact on the tumour stroma remains unclear. This study developed novel in vitro and in vivo mouse models to investigate the role of TGF-β in tumour–stroma interactions under immunocompetent conditions, aiming to evaluate its therapeutic potential in liver cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Mouse liver tumour cell lines were established by hydrodynamic tail vein injection of two different combinations of transposon vector constructions: <i>MYC</i>-<i>LucOS;CTNNB1;SB13</i> (AL1099 cells) and <i>MYC</i>-<i>Luc;CTNNB1;SB13</i> (AL1184 cells) to be used in in vitro and in vivo studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>These cell lines exhibited contrasting phenotypes and responses to TGF-β. We selected AL1099 cells, which displayed an epithelial phenotype and responded to TGF-β with growth inhibition, apoptosis, and induction of Epithelial-Mesenchymal Transition (EMT), and AL1184 cells, which exhibited a mesenchymal-like phenotype and showed enhanced proliferation in response to TGF-β. Both cell lines demonstrated robust growth in 2D and 3D cultures and were co-cultured with RAW 264.7 macrophages, GRX hepatic stellate cells, or both, to explore tumour-stroma interactions. Importantly, AL1099 and AL1184 cells were able to grow in vivo, forming tumours in syngeneic orthotopic models suitable for pharmacological studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Together, these findings highlight the value of these models for advancing therapeutic strategies targeting TGF-β, either alone or in combination with immunotherapy, in liver cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70351","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Scaffold-Free Human Multilineage Spheroid Model for Early Stage Cholangiopathies Driven by Cholangiocyte Senescence","authors":"Cheuk-Ting Wu,&nbsp;Anja Moncsek,&nbsp;Joachim Mertens","doi":"10.1111/liv.70352","DOIUrl":"10.1111/liv.70352","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Cholangiopathies, including primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and post-COVID-19 cholangiopathy (PCC), involve chronic cholangiocyte injury, senescence, epithelial–stromal crosstalk, and progressive fibrosis. However, effective in vitro models to capture these interactions are limited. Here, we present a scaffold-free 3D multilineage spheroid model, composed of hepatocyte-like cells (HepG2), cholangiocytes (H69), and hepatic stellate cells (LX-2), designed to recapitulate early fibrogenic responses driven by senescent cholangiocytes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cholangiocyte senescence was induced via ionising radiation prior to spheroid assembly. Fibrosis progression was assessed by mRNA expression of hepatic stellate cell (HSC) activation markers, immunofluorescence, and Masson's trichrome staining, in both direct HSC co-culture and spheroids. To evaluate therapeutic potential, spheroids were treated with A-1331852, a selective Bcl-xL inhibitor known to induce apoptosis in senescent cells in PSC and PBC mouse models Drug efficacy was measured by apoptosis induction, reduction of fibrosis, and modulation of stromal activation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Senescent cholangiocytes induced robust HSC activation and promoted extracellular matrix (ECM) deposition, mimicking early fibrogenesis. Treatment with A-1331852 selectively induced apoptosis in senescent cholangiocytes and activated HSCs, leading to a marked reduction in fibrosis, consistent with murine PSC and PBC models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This 3D multilineage spheroid model offers a mechanistically relevant and scalable platform to study cholangiocyte senescence-driven fibrosis. Its applicability to senolytic drug testing supports its use in preclinical screening and translational research across a spectrum of cholangiopathies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70352","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impairment of Regenerative and Metabolic Pathways in Intestinal Organoids From Patients With MASLD-Cirrhosis","authors":"Agnese Filippello,&nbsp;Alessandra Scamporrino,&nbsp;Stefania Di Mauro,&nbsp;Angela Maria Amorini,&nbsp;Grete Francesca Privitera,&nbsp;Anna Fichera,&nbsp;Paola Bonaccorso,&nbsp;Martina Musumeci,&nbsp;Antonino Di Pino,&nbsp;Roberto Scicali,&nbsp;Roberta Malaguarnera,&nbsp;Maria Teresa Di Martino,&nbsp;Salvatore Piro,&nbsp;Federico Salomone","doi":"10.1111/liv.70331","DOIUrl":"10.1111/liv.70331","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Gut-liver axis has been implicated in the pathophysiology of cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD), an in vitro model for studying epithelial gut dysfunction in MASLD is lacking. In this study, we aimed to characterise intestinal organoids derived from subjects with MASLD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Intestinal organoids were obtained from duodenal samples of individuals with non-fibrotic MASLD and with MASLD-cirrhosis. After 7 to 10 days of culture, RNA extraction, transcriptomic analysis and real-time PCR were performed. Energetic and redox <i>status</i> of organoids were assessed by chromatographic analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Microarray analysis showed approximately 600 dysregulated transcripts in organoids isolated from patients with MASLD-cirrhosis compared to non-fibrotic MASLD. Bioinformatic analysis indicated that dysregulated transcripts were involved in pathways related to regeneration and pluripotency of stem cells and regulating mitochondrial metabolism and hypoxia. Overall, chromatographic analysis demonstrated that energetic <i>status</i> was remarkably impaired in both differentiated and undifferentiated organoids from cirrhotic patients compared to steatotic subjects. In either undifferentiated or differentiated organoids from cirrhotic subjects, the triphosphate sum, the ATP/ADP and NAD⁺/NADH ratios were lower in MASLD-cirrhosis, indicating a decline in the phosphorylating capacity and a mitochondrial derangement of duodenal cells. In addition, we found lower levels of reduced glutathione, NADPH and UDP-glucuronic acid in undifferentiated and differentiated cells from cirrhotics indicating impairment of antioxidant defence and of response to xenobiotics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study provides a comprehensive view of intestinal epithelial dysfunction in MASLD-cirrhosis, characterised by a cluster of regenerative and metabolic disturbances.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to Editor—TIPSEMS-VB Trial Reappraised: Infection Control, HE Prophylaxis, and Ischemic Hepatitis Considerations","authors":"Sushrut Singh,&nbsp;Vinod Arora,&nbsp;Shiv Kumar Sarin","doi":"10.1111/liv.70346","DOIUrl":"https://doi.org/10.1111/liv.70346","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcopenia—A Valuable Imaging Biomarker for Disease Progression in Patients With Primary Sclerosing Cholangitis (PSC)?","authors":"Alena Levers,&nbsp;Judith Pantke,&nbsp;Filip Klimeš,&nbsp;Henrike Lenzen,&nbsp;Daniel Düx,&nbsp;Richard Taubert,&nbsp;Heiner Wedemeyer,&nbsp;Frank Wacker,&nbsp;Kristina I. Ringe","doi":"10.1111/liv.70328","DOIUrl":"https://doi.org/10.1111/liv.70328","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>We aimed to ascertain the prevalence of sarcopenia in patients with primary sclerosing cholangitis (PSC) and to assess the prognostic value as a biomarker for disease outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We collected data from 224 patients (148 male, 76 female; mean age 41 years) from January 2002 to December 2021, with a confirmed diagnosis of PSC who underwent magnetic resonance imaging (MRI). Muscle mass was quantified at the level of the third lumbar vertebra by measurement of psoas muscle thickness (PMT) and total psoas muscle area (PMA). Sarcopenia was defined according to previously published cut-off values. Muscle mass and the prevalence of sarcopenia were correlated with patient and disease characteristics, prognostic scoring systems (model for end-stage liver disease (MELD) score; Mayo Risk Score; Amsterdam-Oxford PSC Score) and clinical endpoints (liver transplantation, cirrhosis decompensation, liver-related death).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-eight patients reached a total of 104 clinical endpoints (liver transplantation <i>n</i> = 57, cirrhosis decompensation <i>n</i> = 28, liver-related death <i>n</i> = 19). Sarcopenia was prevalent in 27.7% and 51.3%, respectively (according to the definition of PMT and PMA). Sarcopenia was significantly more prevalent in female patients and in patients without IBD (<i>p</i> &lt; 0.05). A slight but significant negative correlation of muscle mass was noticed with the MELD (<i>r</i> = −0.244, <i>p</i> = 0.001) and Mayo Risk Score (<i>r</i> = −0.13, <i>p</i> = 0.046). At follow-up, sarcopenia was associated with an inferior liver-related event-free survival (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Sarcopenia is highly prevalent in a large PSC cohort from a tertiary care centre, even more frequent in female patients and in patients without concomitant IBD. Furthermore, the presence of sarcopenia in PSC patients is associated with an inferior liver-related event-free survival.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}